GeneDx Holdings Corp. (NASDAQ: WGS) is a Healthcare company (Medical - Diagnostics & Research) with a market capitalization of $1.4B. The Maz Rating grades it against the other companies in its sector.
GeneDx Holdings Corp.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $47.29, GeneDx Holdings Corp. trades at 3.1x sales and 5.8x book value. Over the last twelve months it generated about $462M of revenue and a net loss of $114M. It runs a gross margin of 67.6%, an operating margin of -14.7% and a net margin of -24.1%. It shows return on equity of -42.3%, return on invested capital of -14.7% and a free cash flow yield of -7.1%. On the balance sheet: a debt-to-equity ratio of 0.88 and a current ratio of 4.16. Over the past 52 weeks the share price ranged from $32.21 to $170.87, with a beta of 1.99.
GeneDx Holdings Corp. does not currently pay a dividend.
11 Wall Street analyst ratings cover the stock: 10 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, GeneDx Holdings Corp. (WGS) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and MSCI, and fails FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 6.53% / 30% · (Cash+Inv) / Mkt Cap (36m) 7.59% / 30% · Interest income / Revenue 0.00% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 6.53% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 7.59% / 33% · Receivables / Mkt Cap (36m) 4.11% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 6.53% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 7.59% / 33.33% · Receivables / Mkt Cap (24m) 4.11% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 19.5% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 31.6% / 33.33% · Receivables / Avg Assets (4Q) 16.0% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| FTSE | Debt / Total Assets 27.8% / 33.33% · (Cash+ST Inv) / Total Assets 32.3% / 33.33% · (Cash+Recv) / Total Assets 49.8% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
It depends on the standard you follow. As of September 2026, GeneDx Holdings Corp. (WGS) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and MSCI, and fails FTSE.
Yes. GeneDx Holdings Corp. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
GeneDx Holdings Corp. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.